211 related articles for article (PubMed ID: 29665050)
1. Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90.
Tao H; Chen YY; Sun ZW; Chen HL; Chen M
J Cell Biochem; 2018 Aug; 119(8):6623-6632. PubMed ID: 29665050
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Bali P; Pranpat M; Bradner J; Balasis M; Fiskus W; Guo F; Rocha K; Kumaraswamy S; Boyapalle S; Atadja P; Seto E; Bhalla K
J Biol Chem; 2005 Jul; 280(29):26729-34. PubMed ID: 15937340
[TBL] [Abstract][Full Text] [Related]
3. Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90.
Liu P; Xiao J; Wang Y; Song X; Huang L; Ren Z; Kitazato K; Wang Y
Mol Med; 2021 Sep; 27(1):110. PubMed ID: 34530730
[TBL] [Abstract][Full Text] [Related]
4. Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
Yu S; Cai X; Wu C; Liu Y; Zhang J; Gong X; Wang X; Wu X; Zhu T; Mo L; Gu J; Yu Z; Chen J; Thiery JP; Chai R; Chen L
Int J Biol Sci; 2017; 13(4):505-517. PubMed ID: 28529458
[TBL] [Abstract][Full Text] [Related]
5. HDAC6 inhibition by tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness.
Leyk J; Daly C; Janssen-Bienhold U; Kennedy BN; Richter-Landsberg C
Cell Death Dis; 2017 Aug; 8(8):e3028. PubMed ID: 29048427
[TBL] [Abstract][Full Text] [Related]
6. MiR-601 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma (ESCC) by targeting HDAC6.
Liu C; Tian X; Sun HB; Wang ZF; Jiang LF; Li ZX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1069-1076. PubMed ID: 30779074
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344.
Dawood M; Fleischer E; Klinger A; Bringmann G; Shan L; Efferth T
Pharmacol Res; 2020 Oct; 160():105076. PubMed ID: 32659428
[TBL] [Abstract][Full Text] [Related]
8. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.
Ai J; Wang Y; Dar JA; Liu J; Liu L; Nelson JB; Wang Z
Mol Endocrinol; 2009 Dec; 23(12):1963-72. PubMed ID: 19855091
[TBL] [Abstract][Full Text] [Related]
9. NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells.
Pai JT; Hsu CY; Hua KT; Yu SY; Huang CY; Chen CN; Liao CH; Weng MS
Molecules; 2015 May; 20(5):8000-19. PubMed ID: 25946558
[TBL] [Abstract][Full Text] [Related]
10. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
Fiskus W; Ren Y; Mohapatra A; Bali P; Mandawat A; Rao R; Herger B; Yang Y; Atadja P; Wu J; Bhalla K
Clin Cancer Res; 2007 Aug; 13(16):4882-90. PubMed ID: 17699868
[TBL] [Abstract][Full Text] [Related]
11. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
Eur J Med Chem; 2020 Mar; 190():112086. PubMed ID: 32058238
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological blockade of HDAC6 attenuates cancer progression by inhibiting IL-1β and modulating immunosuppressive response in OSCC.
Mahale A; Routholla G; Lavanya S; Sharma P; Ghosh B; Kulkarni OP
Int Immunopharmacol; 2024 May; 132():111921. PubMed ID: 38547770
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation.
Chi Z; Byeon HE; Seo E; Nguyen QT; Lee W; Jeong Y; Choi J; Pandey D; Berkowitz DE; Kim JH; Lee SY
Pharmacol Res; 2019 Aug; 146():104281. PubMed ID: 31125601
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells.
Asthana J; Kapoor S; Mohan R; Panda D
J Biol Chem; 2013 Aug; 288(31):22516-26. PubMed ID: 23798680
[TBL] [Abstract][Full Text] [Related]
16. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.
Wu X; Wanders A; Wardega P; Tinge B; Gedda L; Bergstrom S; Sooman L; Gullbo J; Bergqvist M; Hesselius P; Lennartsson J; Ekman S
Br J Cancer; 2009 Jan; 100(2):334-43. PubMed ID: 19142186
[TBL] [Abstract][Full Text] [Related]
17. Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.
Cao J; Lv W; Wang L; Xu J; Yuan P; Huang S; He Z; Hu J
Cell Death Dis; 2018 Jul; 9(8):817. PubMed ID: 30050135
[TBL] [Abstract][Full Text] [Related]
18. MeCP2 deficiency is associated with reduced levels of tubulin acetylation and can be restored using HDAC6 inhibitors.
Gold WA; Lacina TA; Cantrill LC; Christodoulou J
J Mol Med (Berl); 2015 Jan; 93(1):63-72. PubMed ID: 25209898
[TBL] [Abstract][Full Text] [Related]
19. Acetylation of Hsp90 reverses dexamethasone-mediated inhibition of insulin secretion.
Zhu K; Zhang Y; Zhang J; Zhou F; Zhang L; Wang S; Zhu Q; Liu Q; Wang X; Zhou L
Toxicol Lett; 2020 Mar; 320():19-27. PubMed ID: 31778773
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.
Bao XH; Takaoka M; Hao HF; Fukazawa T; Yamatsuji T; Sakurama K; Takigawa N; Nakajima M; Fujiwara T; Naomoto Y
Oncol Rep; 2013 Jan; 29(1):45-50. PubMed ID: 23064324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
